Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress
September 05 2017 - 7:30AM
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in
commercialization and development of prescription ophthalmic
pharmaceuticals, today announced that data from 7 ILUVIEN® post
marketing studies involving 1,586 eyes to be presented during the
17th European Society of Retina Specialists Congress (EURETINA),
September 7-10, 2017, in Barcelona. Seven presentations will be
given by speakers from the podium, while there will be 20
electronic posters that will be available throughout the meeting
for review by EURETINA attendees and available on the EURETINA
website following the meeting. Additionally, two presentations will
be given on the effects of a fluocinolone implant on posterior
uveitis.
On Friday, September 8, Alimera will sponsor a symposium as part
of the EuroTimes Satellite Education Program. Entitled "Continuous
Microdosing with ILUVIEN®: Real-world Optimisation of the Treatment
of Chronic DME," the lunchtime event will be moderated by Hans
Hoerauf from the Department of Ophthalmology, University of
Goetingen, Germany and Borja Corcóstegui from the Institut
Microcirurgia Ocular, Barcelona, Spain.
Panel participants include: Anat Loewenstein from Department of
Ophthalmology, Tel Aviv Medical Center, and the Sackler Faculty of
Medicine, Tel Aviv University, Israel; Francisco Goñi from Centro
de Tratamiento Integral del Glaucoma – Centro Médico Teknon,
Barcelona, Spain; and, Bernardete Pessoa from Hospital de Santo
Antonio, Porto, Portugal.
The scheduled times, titles and locations of the nine speaker
presentations are as follows:
- U. Chakravarthy, S. Taylor, C. Bailey, F. Koch, J. Souza
UKILUVIEN® (190 micrograms fluocinolone acetonide) real-life safety
and effectiveness following usage in three European countries –
results from the 2016 extract of data from the ILUVIEN® Registry
Safety, Thursday, September 7, 9:18 a.m., Room 117 (Level 1).
- A. Augustin GERMANYResults from the RETRO-IDEAL study assessing
the real-world ILUVIEN® (fluocinolone acetonide) outcomes in
patients with chronic diabetic macular edema (DME) up to 3 years
after therapy was initiated, Thursday, September 7, 2:30 p.m., Room
117 (Level 1).
- C. Currie, S. Holden, D. Owens UKEvaluation of the clinical
effectiveness in routine practice of the fluocinolone acetonide
intravitreal implant in patients with diabetic macular edema,
Thursday, September 7, 2:48 p.m., Room 117 (Level 1).
- L. Weber, S. Marx, G. Auffarth, S. Sel, A. Scheuerle, T.
Tandogan, R. Khoramnia GERMANYFluocinolone acetonide intravitreal
implant for treatment of non-infectious uveitic macular edema,
Friday, September 8, 12:06 p.m., Room 111 (Level 1).
- C. Pavesio UKAn injectable fluocinolone acetonide intravitreal
insert in patients with chronic non-infectious uveitis affecting
the posterior segment of the eye: Effects on macular edema at 6
months, Friday, September 8, 12:18 p.m., Room 111 (Level 1).
- J. Coelho, B. Pessoa, A. Abreu, N. Correia, N. Ferreira, J.
Melo Beirao, A. Meireles PORTUGALEfficacy and safety of
fluocinolone acetonide implant in vitrectomised and
non-vitrectomized eyes for treatment of chronic diabetic macular
edema, Saturday, September 9, 3:30 p.m., Room 120 (Level 1).
- M. Rehak, M. Tuisl, C. Jochmann, P. Wiedemann
GERMANYFluocinolone acetonide intravitreal implant for treatment of
diabetic macular edema. Long term real life results, Saturday,
September 9, 5:18 p.m., Room 120 (Level 1).
- A. Meireles, C. Teixeira, J. Castro e Sousa, M. Falcao, J.
Coelho, R. Goncalves, B. Pessoa PORTUGALReport of 12 months
efficacy and safety of ILUVIEN® (0.2 μg/d fluocinolone acetonide
[FAC]) for chronic diabetic macular edema in Portugal, Sunday,
September 10, 8:42 a.m., Room 120 (Level 1).
- D. Sahota, H. Ibrahim, R. Sivaraj UKIdentifying patients
appropriate for treatment with fluocinolone acetonide (ILUVIEN®).
When do we switch from anti-VEGF in diabetic macular edema? A
retrospective audit in a UK single-center setting, Sunday,
September 10, 11:06 a.m., Room 117 (Level 1).
About ILUVIEN
U.S. website www.ILUVIEN.com
ILUVIEN'S U.S. Indication
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant approved in the U.S. to
treat diabetic macular edema in patients who have been previously
treated with a course of corticosteroids and did not have a
clinically significant rise in intraocular pressure. Each ILUVIEN
implant is designed to release submicrogram levels of fluocinolone
acetonide, a corticosteroid, for 36 months.
ILUVIEN'S E.U. Indication
ILUVIEN is indicated for the treatment of vision impairment
associated with chronic diabetic macular oedema, considered
insufficiently responsive to available therapies.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera Sciences (NASDAQ:ALIM), founded in June 2003,
is a pharmaceutical company that specializes in the
commercialization and development of prescription ophthalmic
pharmaceuticals. Alimera is presently focused on diseases affecting
the back of the eye, or retina, because these diseases are not well
treated with current therapies and will affect millions of people
in our aging populations. Alimera’s commitment to retina
specialists and their patients is manifest in Alimera’s product and
development portfolio designed to treat early- and late-stage
diseases. For more information, please
visit www.alimerasciences.com.
For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
kbrazel@bellsouth.net
For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2024 to May 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From May 2023 to May 2024